Determinants of Activity at Human Toll-like Receptors 7 and 8: Quantitative Structure–Activity Relationship (QSAR) of Diverse Heterocyclic Scaffolds
作者:Euna Yoo、Deepak B. Salunke、Diptesh Sil、Xiaoqiang Guo、Alex C. D. Salyer、Alec R. Hermanson、Manoj Kumar、Subbalakshmi S. Malladi、Rajalakshmi Balakrishna、Ward H. Thompson、Hiromi Tanji、Umeharu Ohto、Toshiyuki Shimizu、Sunil A. David
DOI:10.1021/jm500744f
日期:2014.10.9
strict dependence of the selectivity for TLR7 vis-à-vis TLR8 on the electronic configurations of the heterocyclic systems, which we sought to examine quantitatively with the goal of developing “heuristics” to define structural requisites governing activity at TLR7 and/or TLR8. We undertook a scaffold-hopping approach, entailing the syntheses and biological evaluations of 13 different chemotypes. Crystal
Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
申请人:3M Innovative Properties Company
公开号:US20040122041A1
公开(公告)日:2004-06-24
Thiazolo-, oxazolo- and selenazolo[4,5-c]quinolin-4-amines and analogs thereof are described including methods of manufacture and the use of novel intermediates. The compounds are immunomodulators and induce cytokine biosynthesis, including interferon and/or tumor biosynthesis, necrosis factor, and inhibit the T-helper-type 2 immune response. The compounds are further useful in the treatment of viral and neoplastic diseases.
Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
申请人:Iovance Biotherapeutics, Inc.
公开号:US11357841B2
公开(公告)日:2022-06-14
Methods of expanding tumor infiltrating lymphocytes (TILs) using a potassium channel agonist, such as a KCa3.1 (IK channel) agonist, and uses of such expanded TILs in the treatment of diseases such as cancer are disclosed herein.